Patents by Inventor Le Sun
Le Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190130804Abstract: The disclosure provides an array substrate, a display device, a detecting apparatus and a detecting method for detecting a defect connection of a data line. A data signal input bus of the array substrate of the present disclosure applies a data signal to each pixel unit, and a detection line is added on one side of the array substrate opposite to the data signal input bus, when the product is detected, the data signal input bus inputs the normal data signal, the detection line on the other side inputs a signal having a polarity contrary to that of the data signal. At a position of the data line existing defect connection, heat is generated and the data line is burnt at the position existing defect connection.Type: ApplicationFiled: October 25, 2018Publication date: May 2, 2019Inventors: Wei ZHANG, Yezhou FANG, Le SUN, Wenlong ZHANG, Guangshuai WANG
-
Patent number: 10216332Abstract: A color filter substrate and an in-cell touch display device are disclosed. The color filter substrate including a display region and a non-display region surrounding the display region, wherein the color filter substrate further includes a conductive antistatic layer, and the antistatic layer is only disposed in the non-display region. The in-cell touch display device can eliminate static electricity under the premise of having no influence on touch function, and the in-cell touch display device is provided with an enhanced anti-electrostatic capability.Type: GrantFiled: July 15, 2016Date of Patent: February 26, 2019Assignees: BOE TECHNOLOGY GROUP CO., LTD., ORDOS YUANSHENG OPTOELECTRONICS CO., LTD.Inventors: Le Sun, Yezhou Fang, Zhengwen Pan, Wei Zhang, Kunpeng Zhang
-
Publication number: 20190010227Abstract: Disclosed herein are humanized anti-Epidermal Growth Factor (EGF) Receptor antibodies which can inhibit the proliferation of cells expressing the EGF receptor. Humanized anti-EGFR antibodies are capable of binding to the surface of cells and killing the EGF receptor overexpression cells. The invention presents the humanized anti-EGFR antibodies which bind to different epitope and inhibit the tumor formation in a different way than Erbitux. Most importantly, once bound to the surface EGFR, these new anti-EGFR antibodies will internalize rather quickly, which made them ideal candidate for antibody drug conjugation and other biotherapy. The invention also features method of humanization which leads to 90% of the amino acid sequences are human sequence, and significantly reduce the risk of human anti-mouse immunogenicity. The present invention also demonstrated that the humanized anti-EGFR antibodies have the affinity to EGFR in the range of 2.Type: ApplicationFiled: March 6, 2015Publication date: January 10, 2019Inventor: Le SUN
-
Publication number: 20180237321Abstract: Metal bioremediation and metal mining strategies can include compositions and methods.Type: ApplicationFiled: February 2, 2018Publication date: August 23, 2018Applicant: Massachusetts Institute of TechnologyInventors: George Le-Le Sun, Angela M. Belcher
-
Publication number: 20180200354Abstract: The present invention relates to the discovery that inhibition of Dickkopf2 (DKK2) increases CD8+ cytotoxic T lymphocyte (CTL) activity, attenuates tumor angiogenesis, and hence suppresses tumor formation. Thus, in various embodiments described herein, the methods of the invention relate to methods of treating cancer by administering to a patient an effective amount of DKK2 gene depleting agent, methods for providing anti-tumor immunity and anti-tumor angiogenesis in a subject, methods of stimulating a T cell mediated immune response to a cell population or a tissue and suppressing tumor angiogenesis in a subject. Additionally, the current invention includes methods of diagnosing a cancer or a predisposition of developing a cancer or a metastasis and methods for determining the use of immunotherapy treatment or cancer vaccine for treating cancer. Furthermore, the invention encompasses a pharmaceutical composition for treating cancer as well as a kit for carrying out the aforementioned methods.Type: ApplicationFiled: June 30, 2015Publication date: July 19, 2018Inventors: Dianqing WU, Le SUN
-
Publication number: 20180107337Abstract: A color filter substrate and an in-cell touch display device are disclosed. The color filter substrate including a display region and a non-display region surrounding the display region, wherein the color filter substrate further includes a conductive antistatic layer, and the antistatic layer is only disposed in the non-display region. The in-cell touch display device can eliminate static electricity under the premise of having no influence on touch function, and the in-cell touch display device is provided with an enhanced anti-electrostatic capability.Type: ApplicationFiled: July 15, 2016Publication date: April 19, 2018Applicants: Boe Technology Group Co., Ltd., Ordos Yuansheng Optoelectronics Co., Ltd.Inventors: Le SUN, Yezhou FANG, Zhengwen PAN, Wei ZHANG, Kunpeng ZHANG
-
Publication number: 20170327570Abstract: Disclosed herein are low immunogenic human anti-TNF-? antibodies which can inhibit the apopotosis of cells induced by TNF-?. The invented low immunogenic human anti-TNF-? antibodies are capable of binding to TNF-? specifically. The invention presents the human anti-TNF-? antibodies which bind to TNF-? with similar affinities as Adalimumab. Most importantly, the invented human anti-TNF-? antibodies showed reduced immunogenicities in vivo, which made them safer candidate for antibody drug and other biotherapy. The invention also features method of de-immunogenicity of antibody drugs by identification, replacement of high immunogenic FR sequence(s) of the human antibody with low immunogenic FR sequences from other human IgGs, and significantly reduce the risk of human anti-human immunogenicity and improve the efficacy of antibody drugs.Type: ApplicationFiled: March 18, 2015Publication date: November 16, 2017Inventors: Le SUN, Xiaogang ZHANG, Maohua LEE, Cuijuan ZHANG
-
Patent number: 8088373Abstract: Disclosed herein are antitumor compositions and methods of interfering with the biological activity of PC cell derived growth factor (PCDGF), anti-PCDGF receptor antibodies, fragments thereof, and methods of making anti-PCDGF receptor antibodies. The methods involve inhibiting the proliferation of tumor cells expressing the PCDGF receptor by contacting the surface of the cell with anti-PCDGF receptor antibodies. Anti-PCDGF receptor antibodies are capable of binding to the surface of a cell and interfering with the binding of PCDGF to its receptor. Also provided are compositions comprising anti-PCDGF receptor antibodies and cytotoxic molecules (e.g., toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides).Type: GrantFiled: June 19, 2008Date of Patent: January 3, 2012Assignee: A&G Pharmaceutical, Inc.Inventors: Ginette Serrero, Le Sun
-
Publication number: 20100266620Abstract: The present invention features immunoconjugates which comprise therapeutic agents coupled to antibodies that specifically recognize pathogen surface antigens. These immunoconjugates can be used to treat or prevent infectious diseases. Upon administration of an immunoconjugate of the present invention to an infected host, the immunoconjugate binds to a specific antigen on the surface of the targeted pathogen (e.g., virus). As the pathogen enters the host cells, the therapeutic agent(s) in the immunoconjugate destroys the infected host cells (and, preferably, the bound pathogen), thereby preventing the replication and transmission of the pathogen. In one embodiment, the immunoconjugates of the present invention specifically recognize surface/envelope antigens of the following viruses: HIV, HBV, HCV, EBV, influenza virus, and SARS associated coronavirus.Type: ApplicationFiled: January 19, 2007Publication date: October 21, 2010Inventor: Le Sun
-
Patent number: 7560095Abstract: Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of normal human tissues. The corresponding cancer-specific antigen or antigens with an apparent molecular weight of 40-52 130-200 kDa and polynucleotides encoding the antigen and the CDR regions of the antibody are also disclosed, as well as methods for diagnosis, prognosis and treatment of human breast cancer. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of cancers. The antibody-recognized cancer-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing cancer cells.Type: GrantFiled: April 22, 2004Date of Patent: July 14, 2009Assignee: A & G Pharmaceutical, Inc.Inventors: Le Sun, Ginette Serrero, Joe Corvera, Yudong Hou
-
Publication number: 20080311120Abstract: Disclosed herein are antitumor compositions and methods of interfering with the biological activity of PC cell derived growth factor (PCDGF), anti-PCDGF receptor antibodies, fragments thereof, and methods of making anti-PCDGF receptor antibodies. The methods involve inhibiting the proliferation of tumor cells expressing the PCDGF receptor by contacting the surface of the cell with anti-PCDGF receptor antibodies. Anti-PCDGF receptor antibodies are capable of binding to the surface of a cell and interfering with the binding of PCDGF to its receptor. Also provided are compositions comprising anti-PCDGF receptor antibodies and cytotoxic molecules (e.g., toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides).Type: ApplicationFiled: June 19, 2008Publication date: December 18, 2008Applicant: A&G Pharmaceutical, Inc.Inventors: Ginette Serrero, Le Sun
-
Patent number: 7411045Abstract: Disclosed herein are antitumor compositions and methods of interfering with the biological activity of PC cell derived growth factor (PCDGF), anti-PCDGF receptor antibodies, fragments thereof, and methods of making anti-PCDGF receptor antibodies. The methods involve inhibiting the proliferation of tumor cells expressing the PCDGF receptor by contacting the surface of the cell with anti-PCDGF receptor antibodies. Anti-PCDGF receptor antibodies are capable of binding to the surface of a cell and interfering with the binding of PCDGF to its receptor. Also provided are compositions comprising anti-PCDGF receptor antibodies and cytotoxic molecules (e.g., toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides).Type: GrantFiled: November 19, 2002Date of Patent: August 12, 2008Assignee: A&G Pharmaceutical, Inc.Inventors: Ginette Serrero, Le Sun
-
Publication number: 20070196274Abstract: The invention provides therapeutic or diagnostic antibodies with modified N— or C-terminal sequences that are enriched with lysine or tyrosine residues. These lysine or tyfosine residues can be used to couple radioisotopes, cytotoxic agents, or detectable labels. The increased stoichiometric ratios of these agents in the antibody conjugates lead to improved therapeutic efficacy or enhanced detection sensitivity. Non-limiting examples of antibodies suitable for the present invention include anti-CD22, anti-ErbB2, anti-VEGF, anti-EGFR, anti-VEGFR, anti-Her-3, anti-Her-4, anti-CEA, anti-CTLA-4, anti-CD4, anti-CD3, anti-CD20, anti-TNF-a, anti-CD11a, anti-Lewis Y antigen, anti-TrailR, anti-IL2R, anti-CD30, anti-CD146, anti-CD147, anti-alpha V integrin beta, anti-CD19, anti-GD2, anti-3H11, anti-EBV, anti-HIV, anti-HBV, anti-HCV, and other disease-specific antibodies.Type: ApplicationFiled: January 19, 2007Publication date: August 23, 2007Inventor: Le Sun
-
Patent number: 7183384Abstract: Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of normal human tissues. The corresponding cancer-specific antigen with an apparent molecular weight of 150 kd and polynucleotides encoding the antigen and the CDR regions of the antibody are Also disclosed are methods for diagnosis, prognosis and treatment of human breast cancer. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of cancers. The antibody-recognized cancer-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing cancer cells.Type: GrantFiled: March 8, 2004Date of Patent: February 27, 2007Assignee: A & G Pharmaceutical, Inc.Inventors: Le Sun, Ginette Serrero, Joe Corvera, Yudong Hu
-
Publication number: 20070025911Abstract: Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of normal human tissues. The corresponding cancer-specific antigen or antigens with an apparent molecular weight of 40-52 130-200 kDa and polynucleotides encoding the antigen and the CDR regions of the antibody are also disclosed, as well as methods for diagnosis, prognosis and treatment of human breast cancer. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of cancers. The antibody-recognized cancer-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing cancer cells.Type: ApplicationFiled: April 22, 2004Publication date: February 1, 2007Applicant: A & G PHARMACEUTICAL, INC.Inventors: Le Sun, Ginette Serrero, Joe Corvera, Yudong Hou
-
Publication number: 20040265930Abstract: Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of normal human tissues. The corresponding cancer-specific antigen with an apparent molecular weight of 150 kd and polynucleotides encoding the antigen and the CDR regions of the antibody are Also disclosed are methods for diagnosis, prognosis and treatment of human breast cancer. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of cancers. The antibody-recognized cancer-specific surface antigens can serve as targets for detecting, diagnosing, inhibiting or killing cancer cells.Type: ApplicationFiled: March 8, 2004Publication date: December 30, 2004Applicant: A&G Pharmaceutical, Inc.Inventors: Le Sun, Ginette Serrero, Joe Corvera, Yudong Hu
-
Publication number: 20030099646Abstract: Disclosed herein are antitumor compositions and methods of interfering with the biological activity of PC cell derived growth factor (PCDGF), anti-PCDGF receptor antibodies, fragments thereof, and methods of making anti-PCDGF receptor antibodies. The methods involve inhibiting the proliferation of tumor cells expressing the PCDGF receptor by contacting the surface of the cell with anti-PCDGF receptor antibodies. Anti-PCDGF receptor antibodies are capable of binding to the surface of a cell and interfering with the binding of PCDGF to its receptor. Also provided are compositions comprising anti-PCDGF receptor antibodies and cytotoxic molecules (e.g., toxins, oncotoxins, mitotoxins, immunotoxins, and antisense oligonucleotides).Type: ApplicationFiled: November 19, 2002Publication date: May 29, 2003Inventors: Ginette Serrero, Le Sun